Mechanism of Gynecomastia in Thyrotoxicosis
Thyrotoxicosis causes gynecomastia through increased hepatic production of sex hormone-binding globulin (SHBG), which binds testosterone more avidly than estradiol, resulting in a decreased free testosterone-to-free estradiol ratio that favors breast tissue proliferation. 1, 2
Hormonal Pathophysiology
Sex Hormone-Binding Globulin (SHBG) Elevation
- Excess thyroid hormone upregulates hepatocyte nuclear factor-4α (HNF4A) in liver cells, which in turn increases SHBG synthesis and secretion. 1
- SHBG binds testosterone with approximately 5-fold higher affinity than estradiol, so when SHBG rises, proportionally more testosterone becomes protein-bound and biologically inactive. 2
- Total serum testosterone and estradiol are both elevated in thyrotoxic men, but free (unbound) testosterone remains normal or low while free estradiol rises above normal. 2
- This imbalance—normal or reduced free testosterone with elevated free estradiol—creates the hormonal milieu that drives gynecomastia. 2, 3
Enhanced Aromatization
- Peripheral tissues (adipose, muscle, liver) exhibit increased aromatase activity in thyrotoxicosis, converting androgens to estrogens at an accelerated rate. 2, 3
- The combination of increased peripheral aromatization and elevated SHBG amplifies the estrogen-to-androgen ratio at the breast tissue level. 3
Gonadal Dysfunction
- Men with thyrotoxicosis demonstrate partial Leydig cell failure, evidenced by blunted testosterone response to hCG stimulation despite elevated basal LH levels. 4
- Basal LH is supranormal and hyperresponds to LRH (luteinizing hormone-releasing hormone) in most thyrotoxic men, indicating impaired negative feedback from estradiol. 4
- Spermatogenesis is frequently impaired, with total sperm counts inversely correlated with serum estradiol concentrations (r = −0.87). 4
Clinical Prevalence and Presentation
- Gynecomastia occurs in 20–40% of men with hyperthyroidism on physical examination, making it a common but often overlooked manifestation. 1, 2
- It may present as the sole or predominant symptom, occasionally preceding classic thyrotoxic features such as weight loss, palpitations, or tremor. 1, 5
- Unilateral or bilateral breast enlargement can be tender and may mimic other breast pathology, necessitating thyroid function testing in all men presenting with unexplained gynecomastia. 1, 5
Resolution with Treatment
- Gynecomastia typically resolves completely within 3 months of achieving euthyroidism with antithyroid medication (thiamazole/methimazole) or definitive therapy (radioactive iodine, thyroidectomy). 1
- Normalization of SHBG and restoration of the free testosterone-to-estradiol ratio occur as thyroid hormone levels decline, reversing the hormonal stimulus for breast tissue proliferation. 1, 2
- Because the pathophysiology is well understood and directly linked to thyroid hormone excess, symptom reduction is predictable once thyrotoxicosis is controlled. 1
Clinical Pitfalls
- Do not attribute gynecomastia solely to obesity, aging, or idiopathic causes without measuring TSH, free T4, and total T3, as thyrotoxicosis is a readily treatable etiology. 1, 6, 5
- Isolated gynecomastia without classic thyrotoxic symptoms can delay diagnosis; maintain a high index of suspicion in men with unexplained breast enlargement, especially if accompanied by weight loss or other subtle signs. 5
- Bilateral diagnostic mammography may be performed to exclude malignancy but does not replace biochemical thyroid evaluation. 5